Doherty Institute's Rapid STI Test: Diagnosing Syphilis, Chlamydia, Gonorrhoea & Herpes in Under an Hour

The Urgent Need for Faster STI Diagnostics in Australia

Australia is facing a growing challenge with sexually transmitted infections (STIs), particularly syphilis, which has seen cases more than double over the past decade. In 2024 alone, the country reported around 6,000 syphilis diagnoses, prompting the Chief Medical Officer to declare it a Communicable Disease Incident of National Significance (CDINS) in August 2025. Gonorrhoea cases have also surged to over 44,000, while chlamydia remains stable but prevalent. These trends are especially concerning in Victoria, where syphilis notifications reached 1,450 in 2025, and congenital syphilis has re-emerged, leading to tragic infant deaths.

Remote and Indigenous communities bear a disproportionate burden, with higher STI rates due to limited access to timely testing and treatment. Current laboratory-based polymerase chain reaction (PCR) tests, the gold standard, require sending samples to centralized labs, often delaying results by days or weeks. This 'loss to follow-up' allows infections to spread unchecked, exacerbating complications like infertility, pelvic inflammatory disease, and adverse pregnancy outcomes.

Such delays highlight the critical gap that innovative diagnostics from Australian universities can fill, positioning institutions like the University of Melbourne at the forefront of public health solutions.

Limitations of Traditional STI Testing Approaches

Traditional STI diagnostics rely heavily on symptom-based screening or single-pathogen tests, which often miss asymptomatic cases—the majority for chlamydia and gonorrhoea. Syphilis, known as the 'great mimicker,' presents symptoms overlapping with herpes simplex virus (HSV), leading to frequent misdiagnosis. Lab PCR tests demand specialized equipment, trained personnel, and infrastructure not available in rural GP clinics or remote health services.

• Samples must be transported to labs, risking degradation and delays.
• Multiple visits required for results and treatment, common in underserved areas.
• Antibiotic-resistant gonorrhoea goes undetected without additional targeted tests.
• High costs and low throughput limit scalability during outbreaks.

In Australia, where STI notifications rose 234% in Victoria from 2005 to 2025, these bottlenecks contribute to ongoing transmission. Researchers at the Doherty Institute recognized this, leveraging advanced molecular tools to revolutionize point-of-care (POC) testing.

The Doherty Institute's Game-Changing Rapid STI Test

Researchers at the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and the Royal Melbourne Hospital, have unveiled a world-first portable POC device. This briefcase-sized innovation detects four major STIs—syphilis (Treponema pallidum), HSV (herpes), Chlamydia trachomatis, and Neisseria gonorrhoeae (gonorrhoea)—simultaneously in under an hour. Led by Dr. Shivani Pasricha, Laboratory Head, and co-first author Matthew O’Neill, the team validated it on 900 clinical samples, the largest dataset for any CRISPR-based STI POC tool.

Developed in collaboration with Bayside Health, Melbourne Sexual Health Centre, Monash University, University of St Andrews (UK), and WEHI, the test uses self-collected urine, saliva, or nasal swabs, making it ideal for clinics worldwide. Published in The Lancet Microbe (DOI: 10.1016/j.lanmic.2025.101289), the study benchmarks it against gold-standard PCR, confirming its readiness for real-world deployment.

Decoding the CRISPR Technology Behind the Test

At its core is a next-generation CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein) diagnostic platform. CRISPR, originally a bacterial immune system, is repurposed here to precisely target pathogen-specific genetic barcodes—DNA for bacteria like syphilis and chlamydia, RNA for viruses like HSV.

1. Sample Collection: Urine, saliva, or swab added to the device.
2. Pre-Amplification: Isothermal amplification boosts target nucleic acids without thermal cycling.
3. CRISPR Detection: Cas enzymes cleave reporter molecules upon binding unique sequences, producing a visible signal (e.g., fluorescent or colorimetric).
4. Multiplexing: Parallel reactions distinguish all four pathogens plus resistance markers.
5. Readout: Results in 50 minutes via simple lateral flow strip or digital reader.

This lab-free process empowers frontline clinicians, contrasting with PCR's complexity. For those pursuing careers in biotech, such innovations underscore CRISPR's versatility in higher ed research jobs.

Impressive Validation and Accuracy Results

Tested on 900 samples from Melbourne Sexual Health Centre, the device achieved 97-100% negative predictive value against PCR. Specific metrics include over 80% accuracy for syphilis, 90% for HSV, and 80% sensitivity for gonorrhoea. Its ability to handle diverse samples without infrastructure rivals lab tests while slashing turnaround time.

A concurrent Lancet Primary Care study (DOI: 10.1016/j.lanprc.2025.100091) supports urban rollout potential. Concurrent research published in The Lancet Primary Care: DOI https://doi.org/10.1016/j.lanprc.2025.100091.

Tackling Antibiotic Resistance in Gonorrhoea

Gonorrhoea's rising resistance threatens standard treatments. The Doherty test uniquely flags a key resistance marker at POC, enabling tailored antibiotics on-site. This prevents treatment failures, crucial as global resistance climbs. In Australia, where resistant strains are emerging, this feature could curb further spread, aligning with national strategies.

For researchers eyeing infectious disease roles, projects like this at Australian universities offer hands-on impact.

Transforming Care in Remote Australian Communities

Remote areas, home to higher STI rates, suffer diagnostic deserts. STI prevalence is 3x higher among poorer, remote populations per Doherty studies. This self-collect POC test bypasses labs, enabling same-day treatment in GP clinics or mobile units. It addresses cultural barriers via non-invasive sampling, potentially halving transmission in high-burden Indigenous communities.

Trials planned for Clinic 34 in Darwin underscore its remote fit. Experts hail it as 'game-changing' for equity.

University of Melbourne's Leadership in Infectious Disease Research

The Doherty Institute exemplifies Uni Melbourne's prowess in translational research. Funded by ARC and Dept of Health, this project bridges academia and health services. It highlights opportunities for PhD/postdocs in molecular diagnostics, with higher-ed jobs booming in virology and genomics.

Collaborations with Monash and WEHI showcase Australia's research ecosystem, fostering innovations that save lives.

Expert Insights and Real-World Potential

'This novel enables accurate diagnosis and treatment immediately... particularly valuable for regional, remote and underserved communities.' — Dr. Shivani Pasricha

'97–100 per cent accuracy... important for safe, evidence-based treatment.' — Matthew O’Neill

RACGP calls it 'world-first,' poised for GP integration. Amid 11 congenital syphilis cases (4 deaths) by mid-2025, experts urge rapid rollout to avert crisis.

Future Outlook: From Lab to Clinics

Implementation trials at Melbourne Sexual Health Centre and Darwin commence 2026, targeting routine use in 5 years. Scalability via low-cost cartridges promises global reach, especially low-resource settings. Australian unis lead, with policy pushes for POC funding.

For aspiring researchers, explore higher ed career advice in this vital field.

Photo by You Le on Unsplash

Career Opportunities in STI Research at Australian Universities

This breakthrough opens doors in research assistant jobs, faculty positions, and postdocs. Uni Melbourne seeks talent in CRISPR and diagnostics. Check university jobs for roles advancing public health.

Engage via Rate My Professor or pursue advice at higher ed career advice.